Syreon Corporation

Clinical Research Programs


Early phase clinical trials (ph. I-lll) incorporate cutting-edge pharmacology and laboratory sciences to evaluate the safety, efficacy and utility of new treatments or indications.

Late phase clinical trials (ph. lllb-IV) speed safe and effective transition from research to clinical practice, and identify target populations, treatment trends, outcomes and barriers to use.

Special approval programs provide access to new and specialized medication in the transitional phase pending marketing approval according to defined guidelines or regulations.

Clinical registries track the natural history, diagnosis, current management, outcomes and complications of patients with chronic disorders to monitor risk factors, treatment choice, clinical effectiveness and costs of new therapeutic agents, diagnostic technology or medical devices.

Clinical management support ensures comprehensive finger-tip information to clinical teams for management of chronic diseases to support clinical guidelines, measure health outcomes and determine clinical and economic value.

  • Therapeutic areas

  • Syreon streamlines the clinical research process to accelerate the safe and effective use of new treatments in clinical practice.

    Therapeutic areas: Our skills encompass a broad range of therapeutic areas including neurology, psychiatry, respirology, cardiology, hepatology, nephrology, endocrinology, gastroenterology, urology, hematology, infectious disease, immunology, transplantation, bone disease, diabetes, metabolic disorders, obesity and cancer.

    Research components: Our studies combine a broad range of diagnostic predictors, pharmacokinetic and pharmacodynamic data, clinical measures, patient-reported outcomes, worker productivity and resource utilization information for seamless and co-ordinated evaluation of therapeutic and economic benefit.